Liposomal doxorubicin: Doxil®

Journal of Oncology Pharmacy Practice

Volumn 2, Issue 4, 1996, Pages 201-210

  Patel, J ^a  

^a Kls Martin   (United States)

Author keywords

Anthracycline; Doxil ; Doxorubicin; Kaposi's sarcoma; Stealth liposome

Indexed keywords

EID: 1542366276     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/107815529600200402     Document Type: Review

References (38)

1. Bangham AD Liposomes: Realizing their promise. Hosp Pract. 1993;27:51-62.
2. Ostro MJ Liposomes. Sci Am. 1987;256:103-111.
3. Lasic D. Liposomes: Synthetic lipid microspheres serve as multipurpose vehicles for the delivery of drugs, genetic material and cosmetics. Am Scientist. 1992;80:20-31.
4. Gabizon A. Liposomal anthracyclines. Hematol Oncol Clin North Am. 1994;8:431-450.
5. Perez-Soler R. Liposomes as carriers of antitumor agents: Toward a clinical reality. Cancer Treat Rev. 1989;16:67- 82.
6. Ostro MJ, Cullis PR Use of liposomes as injectable-drug delivery systems. Am J Hosp Pbarm. 1989;46: 1576-1587.
7. Mayer LD, Bally MB, Hope MJ,et al.Techniques for encapsulating bioactive agents into liposomes. Chem Pbys Lipids. 1986;40:333-345.
8. Liposomal doxorubicin hydrochloride (Doxil®) product information. Menlo Park, NJ: Sequus Pharmaceuticals, 1995.
9. Dorr RT, Von Hoff DD. Cancer Chemotherapy Handbook, 2nd edition. Norwalk, CT: Appleton & Lange, 1994;396-411.
10. Gabizon A., Catane R., Uziely B.,et al.Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 1994;54:987-992.
11. Anon. 1996 Updated Evaluation, Pharmacy and Therapeutics Review, Liposomal doxorubicin. The Formulary, 1996 (Feb.).
12. Woodie MC, Lasic D. Sterically stabilized liposomes. Biocbim Biopbys Acta. 1992;1113:171-199.
13. Working PK, Newman MS, Huang SK,et al.Pharmacokinetics, biodistribution and therapeutic efficacy of doxorubicin encapsulated in Stealth® liposomes (liposomal doxorubicin (Doxil®). J Liposome Res. 1994;4(1):667-687.
14. Bogner JR, Kronawitter U., Rolinski B.,et al.Liposomal doxorubicin in the treatment of advanced AIDS-related Kaposi sarcoma. J Acquir Immune Defic Syndr. 1994;7(5):463- 468.
15. Krown SE, Metroka JC Kaposi's sarcoma in the acquired immune deficiency syndrome: A proposal for uniform evaluation, response, and staging criteria. J Clin Oncol. 1989;7:1201-1207.
16. Hengge UR, Brockmeyer NH, Baumann M.,et al.Liposomal doxorubicin in AIDS-related Kaposi's sarcoma. Lancet. 1993;342:497.
17. Hengge UR, Brockmeyer NH, Rabhofer R.,et al.Fatal hepatic failure with liposomal doxorubicin. Lancet. 1993;341:383.
18. Harrison M., Tomlinson D., Stewart S. Liposomal-entrapped doxorubicin: An active agent in AIDS-related Kaposi's sarcoma. J Clin Oncol. 1995;13: 914-920.
19. Goebel FD, Goldstein D., Goos M.,et al.Efficacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma. [The International SL-DOX Study Group.] Br J Cancer 1996 Apr;73(8):989-94.
20. Gill PS, Wernz, J., Scadden DT,et al.Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol. 1996;14: 2353-2364.
21. Uziely B., Jeffers S., Isacson R.,et al.Liposomal doxorubicin: Antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol. 1995;13:1777-1785.
22. Gabizon A., Isacson R., Libson E.,et al.Clinical studies of liposome-encapsulated doxorubicin. Acta Oncol. 1994;33(7):779-786.
23. Gordon KB, Tajuddin A., Guitart J.,et al.Hand-Foot syndrome associated with liposome-encapsulated doxorubicin toxicity. Cancer 1995;75:2169-2173.
24. Fabian CJ, Molina R., Slavik M.,et al.Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. Invest New Drugs. 1990;8:57- 63.
25. Herman EH, Rahman A., Ferrans VJ,et al.Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation. CancerRes. 1983;43:5427-5432.
26. Rahman A., Kessler A., More N.,et al.Liposomal protection of adriamycin-induced cardiotoxicity in mice. Cancer Res. 1980;40:1532-1537.
27. Rahman A., Fumagalli A., Barbieri B.,et al.Antitumor and toxicity evaluation of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes. Cancer Chemother Pbarmacol. 1986;16:22-27.
28. Rahman A., White G., Moore N.,et al.Pharmacological, toxicological and therapeutic evaluation in mice of doxorubicin entrapped in cardiolipin liposomes. Cancer Res. 1985;45:796-803.
29. Berry G., Billingham M., Alderman E.,et al.Reduced cardiotoxicity of liposomal doxorubicin (Doxil) (pegylated liposomal doxorubicin) in AIDS Kaposi's sarcoma patients compared to a matched control group of cancer patients given doxorubicin. Proc Am Soc Clin Oncol. 1996;15:303.
30. Rahman A., Treat J., Rah JK,et al.A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin. J Clin Oncol. 1990;8: 1093-1100.
31. Conley BA, Egorin MJ, Whitacre MY,et al.Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicin. Cancer Chemother Pbarmacol. 1993; 33:107-112.
32. Cowens JW, Creaven PJ, Greco WR,et al.Initial clinical (phase I) trial of TLC D-99 (Doxorubicin Encapsulated in Liposomes). Cancer Res. 1993;53: 2796-2802.
33. Early E., Shorter S., Sugarman A.,et al.Phase I trial of dose-intense liposomal encapsulated doxorubicin (LED) with G-CSF in patients with advanced soft tissue sarcoma. Proc Am Soc Clin Oncol. 1996;15: 524.
34. Treat J., Greenspan A., Forst D.,et al.Antitumor activity of liposome-encapsulated doxorubicin in advanced breast cancer: Phase II Study. J Natl Cancer Inst. 1990;82:1706-1710.
35. Gabizon A., Peretz T., Sulkes A.,et al.Systemic administration of doxorubicin-containing liposomes in cancer patients: A Phase I study. Eur J Cancer Clin Oncol. 1989;25:1795-1803.
36. Owen RR, Sells RA, Gilmore IT,et al.A phase I clinical evaluation of liposome-entrapped doxorubicin (Lip-Dox) in patients with primary and metastatic hepatic malignancy. Anticancer Drugs. 1992; 3:101-107.
37. Madhavan S., Northfelt DW Lack of vesicant injury following extravasation of liposomal doxorubicin. J Natl Cancer Inst. 1995;87:1556-1557.
38. Doxil® (Sequus). Redbook. Montvale, NJ: Medical Economics, 1996;234.